DBV Technologies: Valuation Remains Largely Unchanged
Edison | Jun 11, 2015 08:43AM ET
Further VIPES responder analyses at EAACI
Additional data from DBV Technologies (PARIS:DBV)’s Phase IIb VIPES trial have been presented at EAACI. A further post hoc analysis applying more rigorous efficacy criteria reinforces the strength of the existing data, in our view. DBV also hosted a well-attended physician symposium, highlighting interest in DBV’s Viaskin products and helping to raise broader awareness, both key for a successful launch. Our valuation is largely unchanged at $1,357m.
Further VIPES analyses presented at EAACI
A new post hoc analysis of VIPES presented at EAACI applied a more rigorous definition of “responder” to the existing dataset. This latest analysis demonstrates that 50% of children (aged 6-11 years) at the highest Viaskin dose responded, compared to 12.9% on placebo (p=0.0039). These new data largely exclude highly sensitive children who may have only had a small increase in the actual quantity of peanut protein consumed, compared to baseline (eg from 1mg on entry to 10mg at 12 months, meeting the >10-fold increase responder definition). These data add to both previously published top-line data and detailed data made available at AAAAI.
To Read the Entire Report Please Click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.